MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, RARE made $673M in revenue. -$575M in net income. Net profit margin of -85.44%.

Income Overview

Revenue
$673M
Net Income
-$575M
Net Profit Margin
-85.44%
EPS
-$5.83
Unit: Million (M) dollars
Revenue Breakdown
    • Product
    • Royalty
Revenue Breakdown
    • Crysvita-Royalty
    • Crysvita
    • Dojolvi
    • Others
Revenue Breakdown
    • North America
    • Latin America
    • EMEA
    • Asia Pacific

Unit: Million (M) dollars (except for numbers of shares and EPS)
Income Statement
2025-12-31
Total revenues
673
Cost of sales
109
Research and development
750
Selling, general and administrative
349
Total operating expenses
1,208
Loss from operations
-535
Interest income
25
Non-cash interest expense on liabilities for sales of future royalties
62
Other income (expense)
1
Loss before income taxes
-571
(provision for) benefit from income taxes
4
Net loss
-575
Net loss per share, basic
-5.83
Net loss per share, diluted
-5.83
Shares used in computing net loss per share, basic
98,600,000
Shares used in computing net loss per share, diluted
98,600,000
Unit: Million (M) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$575M (provision for) benefitfrom income taxes$4M Loss before incometaxes-$571M Other income(expense)$1M Interest income$25M Royalty$304M Product$369M Non-cash interestexpense on liabilities...$62M Loss from operations-$535M Total revenues$673M Total operatingexpenses$1,208M Selling, general andadministrative$349M Research and development$750M Cost of sales$109M

Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Inc. (RARE)